According to the prescribing information, the recommended dosage regimen for the Wegovy pill is as follows
Since there are no head-to-head trials comparing oral semaglutide for obesity to orforglipron, this indirect treatment comparison from the ORION study provides important information that can be used during the shared decision-making process.
Clinical research has generally demonstrated favorable tolerability, though individual responses vary
2030 (USD BILLION) FIGURE 15 GLP-1 AGONISTS MARKET, BY END USER, 2025 VS
Numerous studies have examined the effect of training on BMD in postmenopausal women [43,44,45,46]
8 SUMMIT also demonstrated significant improvements in patient-reported outcomes: at 52 weeks, tirzepatide increased KCCQ-CSS, with a between-group mean difference of 6.9 points, and increased 6-minute walk distance, with a between-group mean difference of 18.3 m